ProCE Banner Activity

Advances in HIV Treatment

Multimedia

Watch and listen as a global panel of expert faculty provides insights on key clinical advances in HIV treatment that have taken place over the past year, including updates in first-line therapy, new switch strategies for patients with viral suppression on their current ART, and new regimens for patients experiencing virologic failure.

Released: November 17, 2022

Share

Faculty

Joseph J. Eron

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Monica Gandhi

Monica Gandhi, MD, MPH

Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco
San Francisco, California

Patrick W. G. Mallon

Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI

Full Professor of Microbial Diseases
Director, Centre for Experimental Pathogen Host Research
School of Medicine
University College Dublin
Dublin, Ireland

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

Joseph J. Eron, Jr., MD

Professor of Medicine
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Joseph J. Eron, Jr., MD: consultant/advisor/speaker: Gilead Sciences, GlaxoSmithKline, Janssen, Merck, ViiV Healthcare; researcher: Gilead Sciences, ViiV Healthcare.

Monica Gandhi, MD, MPH

Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco
San Francisco, California

Monica Gandhi, MD, MPH, has no relevant financial relationships to disclose.

Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI

Full Professor of Microbial Diseases
Director, Centre for Experimental Pathogen Host Research
School of Medicine
University College Dublin
Dublin, Ireland

Patrick W. G. Mallon, MB, BCh, PhD, FRACP, FRCPI: consultant/advisor/speaker: AstraZeneca, Gilead Sciences, Merck Sharp & Dohme, ViiV Healthcare.